A CD40-targeting peptide, OPT501, modulates inflammation in canine diabetes mellitus improving clinical outcomes
This pilot and proof-of-concept study demonstrates that targeting CD40 with a peptide is feasible and impacts the inflammatory status of the recipient CDM dogs, with improved disease management as a result. The C-peptide result is consistent with preservation of islet beta cell health and function. These data support translation of a CD40 targeting peptide approach to human type 1 diabetes.
Authors
- David H. Wagner (ORCID: https://orcid.org/0000-0002-3853-8039)
- Gisela Vaitaitis (ORCID: https://orcid.org/0000-0001-6413-8322)
- Dan Waid
- Christina Sharkey (ORCID: https://orcid.org/0000-0003-4746-7911)
- Steve Sharkey
- Craig B. Webb
- Tracy Webb
Institutions
- Montclair State University (US)
- Optical Physics Company (United States) (US)
- Montclair Hospital Medical Center (US)
- University of Colorado Anschutz Medical Campus (US)
- Colorado State University (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-24
- DOI
- https://doi.org/10.3389/fimmu.2026.1759373
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00